Announcements Trials
Browse Landscape

Phase

Phase NA 22Phase 2 7Phase 4 3Phase 3 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 146Breast Neoplasms 111Prostatic Neoplasms 59Neoplasms 54Multiple Myeloma 54Lung Neoplasms 49Neoplasm Metastasis 40Ovarian Neoplasms 33Colorectal Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 31Leukemia, Lymphocytic, Chronic, B-Cell 31Recurrence 26Leukemia, Myeloid, Acute 26Carcinoma, Renal Cell 25Urinary Bladder Neoplasms 23Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 21Myasthenia Gravis 21Endometrial Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Melanoma 18Lymphoma, Follicular 18Nasopharyngeal Carcinoma 17Fallopian Tube Neoplasms 16Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15Brain Neoplasms 15Stomach Neoplasms 14

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Papillomavirus Infections × 90 days × Clear all
NCT07217145 2026-06-05

PREVENT HPV -Related Cancers Trial

University of Utah

Phase 3 Active not recruiting
1,455 enrolled

Behavior, Communication, Neoplasms, Patient Acceptance of Health Care, Papillomavirus Infections

NCT03998254 2026-06-02

V503-023

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
6,000 enrolled

Papillomavirus Infections

NCT03903562 2026-04-06

V503-024

Merck Sharp & Dohme LLC

Phase 3 Completed
1,990 enrolled 42 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡